Search

Community Bulletin: Limb-girdle Facebook Live Event
Community Bulletin: EMBARK Study (SRP-9001-301) Enrollment Update
Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Sarepta Therapeutics’ Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) (EMBARK)
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments on March 1, 2022
Sarepta Therapeutics Announces the Launch of SareptaCircle to Highlight the Experiences of Individuals and Families Living with Rare Disease
Sarepta Therapeutics anuncia el lanzamiento de SareptaCircle para destacar las experiencias de personas y familias que viven con enfermedades raras